Zibotentan is under clinical development by AstraZeneca and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Zibotentan’s likelihood of approval (LoA) and phase transition for Diabetic Nephropathy took place on 21 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Zibotentan Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Zibotentan is under development for the treatment of diabetic nephropathy, chronic kidney disease (CKD), cirrhosis with features of portal hypertension and microvascular angina. The drug candidate is administered orally in the form of tablet and capsule. It is a selective antagonist of the endothelin-A (ET-A) receptor with antineoplastic activity. It was also under development for intermittent claudication in peripheral artery disease, patients with non-metastatic castrate resistant prostate cancer, epithelial ovarian cancer, fallopian tube cancer, primary serous peritoneal cancer and non-small cell lung cancer .
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
Quick View Zibotentan LOA Data
|Highest Development Stage|